Patents Represented by Attorney, Agent or Law Firm Janet E. Hasak
  • Patent number: 7294483
    Abstract: A process is described for producing a polypeptide heterologous to E. coli wherein E. coli cells comprising nucleic acid encoding the polypeptide are cultured in a culture medium while feeding to the culture medium a transportable organophosphate, such that the nucleic acid is expressed. The polypeptide is then recovered from the cells.
    Type: Grant
    Filed: March 10, 2005
    Date of Patent: November 13, 2007
    Assignee: Genentech, Inc.
    Inventors: Woon-Lam Susan Leung, James R. Swartz
  • Patent number: 7229787
    Abstract: A gram-negative bacterial cell is described that is deficient in a chromosomal gene present in a wild-type such cell which gene shares at least 80% sequence identity with the native sequence of the yfcK gene and encodes an aminopeptidase. Alternatively, a gram-negative bacterial cell is deficient in a chromosomal gene present in a wild-type such cell which gene encodes an aminopeptidase that shares at least 80% sequence identity with the native sequence of aminopeptidase b2324. Either of these types of cells, when comprising a nucleic acid encoding a heterologous polypeptide, produces an N-terminal unclipped polypeptide when it is cultured and the polypeptide recovered, with virtually no N-terminal clipped polypeptide produced as an impurity. Conversely, a method is provided for cleaving an N-terminal amino acid from a polypeptide comprising contacting the polypeptide with an aminopeptidase sharing at least 80% sequence identity with the native sequence of aminopeptidase b2324.
    Type: Grant
    Filed: May 16, 2005
    Date of Patent: June 12, 2007
    Assignee: Genentech, Inc.
    Inventor: John C. Joly
  • Patent number: 7169908
    Abstract: A method for purifying a desired heterologous polypeptide from microbial fermentation broth or homogenate in which it is produced and solubilized is described. This method involves adding to the broth or homogenate an effective amount of a solution of 6,9-diamino-2-ethoxyacridine lactate (ethacridine lactate) to precipitate host cell impurities under conditions wherein the majority of polypeptide remains soluble, and separating the desired polypeptide from the broth or homogenate. The broth or homogenate containing the ethacridine lactate and polypeptide is also disclosed.
    Type: Grant
    Filed: January 8, 2004
    Date of Patent: January 30, 2007
    Assignee: Genentech, Inc.
    Inventors: Philip M. Lester, Josefine Persson
  • Patent number: 7029876
    Abstract: Vectors for producing polypeptides heterologous to prokaryotes are described comprising, along with the polypeptide-encoding nucleic acid, anti-termination nucleic acid that inhibits intragenic transcription termination with a non-lambda promoter therefor and/or nucleic acid encoding a GreA or GreB protein and a promoter therefor. Also described are processes for producing a heterologous polypeptide in prokaryotic host cells utilizing such elements to improve the quality and/or quantity of heterologous polypeptide produced.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: April 18, 2006
    Assignee: Genentech, Inc.
    Inventors: Eriks Sasha Paegle, Dorothea Reilly, Daniel G. Yansura
  • Patent number: 6921659
    Abstract: A gram-negative bacterial cell is described that is deficient in a chromosomal gene present in a wild-type such cell which gene shares at least 80% sequence identity with the native sequence of the yfcK gene and encodes an aminopeptidase. Alternatively, a gram-negative bacterial cell is deficient in a chromosomal gene present in a wild-type such cell which gene encodes an aminopeptidase that shares at least 80% sequence identity with the native sequence of aminopeptidase b2324. Either of these types of cells, when comprising a nucleic acid encoding a heterologous polypeptide, produces an N-terminal unclipped polypeptide when it is cultured and the polypeptide recovered, with virtually no N-terminal clipped polypeptide produced as an impurity. Conversely, a method is provided for cleaving an N-terminal amino acid from a polypeptide comprising contacting the polypeptide with an aminopeptidase sharing at least 80% sequence identity with the native sequence of aminopeptidase b2324.
    Type: Grant
    Filed: September 12, 2002
    Date of Patent: July 26, 2005
    Assignee: Genentech, Inc.
    Inventor: John C. Joly
  • Patent number: 6828118
    Abstract: A process is described for monitoring the effectiveness of a purification process in removing plasminogen activator (PA) endogenous to Chinese hamster ovary (CHO) cells from a sample containing human tPA or variants thereof. This process comprises incubating the sample with a protease capable of specifically cleaving the Arg275-Ile276 bond of human wild-type tPA and then with denaturing/reducing agents in respective amounts effective to reduce the disulfide bonds of human wild-type tPA; subjecting the sample to a reversed-phase high-performance liquid chromatography step, and analyzing the elution profile from the chromatography step for the amount of PA endogenous to the CHO cells present therein.
    Type: Grant
    Filed: May 21, 2003
    Date of Patent: December 7, 2004
    Assignee: Genentech, Inc.
    Inventor: Yuan Xu
  • Patent number: 6828121
    Abstract: An E. coli strain is described that is deficient in chromosomal degP and prc encoding protease DegP and Prc, respectively, and harbors a mutant spr gene that encodes a protein that suppresses growth phenotypes exhibited by strains harboring prc mutants. Preferably, the strain comprises nucleic acid encoding a polypeptide heterologous to the strain, so that a heterologous polypeptide can be produced therefrom.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: December 7, 2004
    Assignee: Genentech, Inc.
    Inventor: Christina Yu-Ching Chen
  • Patent number: 6750321
    Abstract: Peptides are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist peptides are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: June 15, 2004
    Assignee: Genentech, Inc.
    Inventors: Yvonne Man-yee Chen, Ross G. Clark, Andrea G. Cochran, Henry B. Lowman, Iain C. A. F. Robinson, Nicolas J. Skelton
  • Patent number: 6743894
    Abstract: Peptides are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist peptides are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: June 1, 2004
    Assignee: Genentech, Inc.
    Inventors: Yvonne Man-yee Chen, Ross G. Clark, Andrea G. Cochran, Henry B. Lowman, Iain C. A. F Robinson, Nicholas J. Skelton
  • Patent number: 6716602
    Abstract: The invention provides a method for increasing product yield of a polypeptide of interest produced by recombinant host cells, where expression of the polypeptide by the recombinant host cells is regulated by an inducible system. More specifically, the method involves culturing the recombinant host cells under conditions of high metabolic and growth rate and then reducing the metabolic rate of the recombinant host cells at the time of induction of polypeptide expression. In particular, the invention provides a method of increasing product yield of an antibody, growth factor, or protease produced by a recombinant E. coli host cell regulated by an inducible system.
    Type: Grant
    Filed: November 1, 2001
    Date of Patent: April 6, 2004
    Assignee: Genentech, Inc.
    Inventors: Dana Andersen, John Joly, Bradley R. Snedecor
  • Patent number: 6716586
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: April 6, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Patent number: 6713451
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: March 30, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Patent number: 6693078
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: February 17, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Patent number: 6693079
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: February 17, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Patent number: 6689751
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: February 10, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Patent number: 6683053
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: January 27, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Patent number: 6680298
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: January 20, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Patent number: 6677305
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: January 13, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Patent number: 6645775
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: November 11, 2003
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Patent number: 6635619
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which includes peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: October 21, 2003
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson